{"id":"NCT02466386","sponsor":"Shire","briefTitle":"Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years, Diagnosed With Attention-deficit/Hyperactivity Disorder","officialTitle":"A Phase 3, Open-label, Multicenter, 12-Month Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years Diagnosed With Attention-deficit / Hyperactivity Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-08-21","primaryCompletion":"2020-01-03","completion":"2020-01-03","firstPosted":"2015-06-09","resultsPosted":"2021-03-05","lastUpdate":"2021-03-05"},"enrollment":113,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Attention Deficit Hyperactivity Disorder (ADHD)"],"interventions":[{"type":"DRUG","name":"SPD489","otherNames":["Lisdexamfetamine dimesylate"]}],"arms":[{"label":"SPD489","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the long-term safety of SPD489 administered as a daily morning dose (5, 10, 15, 20, and 30 mg/day) in preschool children diagnosed with Attention-deficit/Hyperactivity Disorder (ADHD).","primaryOutcome":{"measure":"Number of Participants With Treatment-Emergent Adverse Events (TEAEs)","timeFrame":"From start of study drug administration up to follow-up (Week 53)","effectByArm":[{"arm":"SPD489","deltaMin":86,"sd":null}],"pValues":[]},"eligibility":{"minAge":"4 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":50,"countries":["United States"]},"refs":{"pmids":["35230142"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":113},"commonTop":["Decreased appetite","Pyrexia","Influenza","Pharyngitis streptococcal","Nasopharyngitis"]}}